RISA Labs, an AI-focused healthtech startup that streamlines oncology operations, has raised $11.1 million (about ₹91 crore) to expand its technology across hospital networks and deepen its presence in the cancer-care ecosystem. The fresh funding will accelerate product development and wider deployments aimed at reducing administrative delays in treatment pathways.
Funding and investor mix
The round was co‑led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures and Ventureforgood. Early backer Binny Bansal also continued his support. Investors cited growing confidence in AI solutions that target operational inefficiencies in healthcare delivery.
Building an AI operating system for oncology workflows
Founded by Kshitij Jaggi and Kumar Shivang, RISA Labs is developing what it describes as an AI operating system for oncology. The platform addresses time‑consuming administrative and clinical tasks that fragment care—such as prior authorisations, benefits verification, insurance coordination and multi‑system data reconciliation.
Oncology workflows often involve disparate electronic systems, lengthy approval cycles and significant manual effort by care teams. RISA Labs uses AI agents to automate repetitive processes across systems, aiming to shorten turnaround times and let clinicians focus more on patient care than paperwork.
Use of funds and expansion plans
The new capital will be used to accelerate product development, expand deployments across US hospitals and cancer care networks, and strengthen integrations with electronic health records, payer platforms and internal clinical tools. A substantial portion of funding is earmarked for engineering and interoperability work to embed the platform into existing healthcare infrastructure.
RISA Labs also plans to scale its customer base by onboarding more oncology providers and enterprise healthcare organisations, with an emphasis on demonstrating measurable improvements in operational efficiency, approval timelines and quality of care delivery.
Early traction and real-world impact
The startup reports early traction: its AI‑driven workflows have automated prior authorisations, benefits checks and other administrative tasks that typically delay cancer treatment. Customers have seen faster approvals and reduced manual workload for staff in many deployments.
Beyond point automation, RISA Labs envisions AI agents acting as a digital extension of care teams—navigating complex processes across systems with minimal human intervention to deliver more consistent, scalable operational performance.
Investor confidence and sector context
Participation by global healthcare investors underscores a rising belief that AI can transform healthcare operations. Continued backing from an Indian entrepreneur like Binny Bansal adds strategic credibility, reflecting investor interest in scalable, tech‑first solutions to systemic healthcare problems.
As RISA Labs enters its next growth phase, healthtech and AI observers will watch whether its platform can deliver sustained efficiency gains and meaningfully improve the patient experience in oncology care.
